Global Glucagon-Like Peptide 1 (GLP-1) Agonist (Tirzepatide, Semaglutide, Dulaglutide, Others) Market Research Report 2024
February 26, 2024 11:24 ET
|
Research and Markets
Dublin, Feb. 26, 2024 (GLOBE NEWSWIRE) -- The "Global Glucagon-Like Peptide 1 (GLP-1) Agonist market (2024 Edition): Analysis by Type, End-Use (Type 2 Diabetes, NASH, Obesity), By Distribution...
North America Sulfonylureas Market Projected to Grow, Hitting USD 3.35 Billion Valuation by 2028 with Notable CAGR of 1.90%
January 30, 2024 20:00 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "North America Sulfonylureas Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)" report has been added to ...
China Diabetes Care Drugs Market to Reach USD 13.73 Billion by 2028, Propelled by Rising Prevalence and Advanced Treatment Options
January 30, 2024 19:57 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "China Diabetes Care Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)" report has been added to ...
RYZODEG Drug & Market Forecast Report 2023-2032: Reveals Comprehensive Insights for Type 1 Diabetes Mellitus Treatment - Mechanism of Action, Clinical Assessments, Market Dynamics, Emerging Competitors
January 30, 2024 06:58 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "RYZODEG Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. Offering an in-depth analysis of the...
Cell Therapies for Type 1 Diabetes: 2023-2030 Industry Outlook Featuring Analysis of Leading Players Novo Nordisk, Sanofi, Vertex Pharmaceuticals, Sernova, and Throne Biotechnologies
January 30, 2024 04:49 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Cell Therapies for Type 1 Diabetes (2023 Edition): Global and Country Analysis By Epidemiology, Pipeline and Target Market Assessment" report has been...
PRV-031 (teplizumab) Drug Insight and Market Forecast to 2032: Highlights Opportunities Across Key Regions
January 29, 2024 12:21 ET
|
Research and Markets
Dublin, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The "PRV-031 Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report reveals extensive insights...
Diabetes Care Advances: LEVEMIR Drug Insight and 2032 Market Forecast Revealed
January 24, 2024 10:50 ET
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "LEVEMIR Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. The healthcare industry has taken a...
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
January 09, 2024 08:30 ET
|
Lexaria Bioscience Corp.
NEW YORK, Jan. 09, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+...
Global Glucagon-like Peptide 1 (GLP-1) Market Soars to $18.75 Billion by 2023, Fueled by Increasing Healthcare Expenditure and Aging Population
November 10, 2023 08:48 ET
|
Research and Markets
Dublin, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The "Global Glucagon-like Peptide 1 (GLP-1) Market (by Product, Route of Administration, & Region): Insights and Forecast with Potential Impact of...
Diabetes Drugs Market Size to Surpass USD 134.08 Billion by 2030, exhibiting a CAGR of 7.8%
October 25, 2023 07:15 ET
|
Fortune Business Insights
Pune, India, Oct. 25, 2023 (GLOBE NEWSWIRE) -- The global diabetes drugs market size was valued at USD 66.15 billion in 2022, and it is expected to expand from USD 79.25 billion in 2023 to USD...